MedTrace Logo

Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity

NCT01960205 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-09-25

No results posted yet for this study

Summary

The purpose of the study is to examine the effect of Saxagliptin in the newly diagnosed people with pre-diabetes and obesity besides lifestyle intervention ,there to evaluate DPP 4 inhibitors of reversing pre-diabetes curative effect to normal blood sugar, and observe its influences on the targets of obesity related metabolic abnormalities, to explore new ways for intervention on populations with pre-diabetes and obesity .

Conditions

Interventions

DRUG

Saxagliptin

5mg a day for 6 months

DRUG

saxagliptin

2.5 mg a day for 6 months

DRUG

metformin

500mg three times a day for 6 months

OTHER

lifestyle intervention

lifestyle intervention for 6 months

Sponsors & Collaborators

  • Chinese Medical Association

    collaborator NETWORK

  • Shandong Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Xinli Zhou, MD, PhD · Shandong Provincial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01960205 on ClinicalTrials.gov